Study
| Double-blind, randomised, phase 3 study (KEYNOTE-716) |
| Newly diagnosed, completely resected stage IIB or IIC melanoma |
| Pembrolizumab (n=483) or placebo (n=486) |
Efficacy
| RFS : 20.9 mos: 85% vs. 76% [ HR: 0.61 (0·45–0·82)] |
| mRFS not reached |
Safety
| Grade >= 3 AEs: 16% vs 4% |
| AEs related death: 0 vs 4 patients |
Lancet. 2022 Apr 30;399(10336):1718-1729.
http://doi.org/10.1016/s0140-6736(22)00562-1
Reviewed by Hasan Cagri Yildirim, MD on May 20, 2022
